

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Immunisation Advisory Committee Provisional recommendations 6 November 2025

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Pneumococcal 20-valent conjugate vaccine for the prevention of invasive pneumococcal, for all children up to 59 months of age, within the context of vaccines and immunisation, subject to criteria	High priority
Pneumococcal 20-valent conjugate vaccine for the prevention of invasive pneumococcal disease, for people at high-risk with eligible conditions, within the context of vaccines and immunisation, subject to criteria	High priority
Pneumococcal 20-valent conjugate vaccine for the prevention of invasive pneumococcal disease, for all adults aged 65 years and older, within the context of vaccines and immunisation	High priority
Nirsevimab for the prevention of respiratory syncytial virus (RSV) for all infants at birth or in their first RSV season, and for high-risk infants entering second RSV season, within the context of vaccines and immunisation, subject to criteria	High priority
RSVPreF3 Vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older within the context of vaccines and immunisation, subject to criteria	Medium priority
RSVPreF3 Vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults aged 65 to 74 years with eligible comorbidities and all 75 years of age and older, within the context of vaccines and immunisation, subject to criteria	High priority

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

[More information about the agenda items considered at the recent Immunisation Advisory Committee meeting can be found on the Pharmac website.](#)